Does the anti-Müllerian hormone truly reflect ovarian response in women with endometrioma?

• Published in: Journal of obstetrics and gynaecology 2019-05, Vol.39 (4), p.516-521
• Main Authors: Inal, Zeynep Ozturk, Engin Ustun, Yaprak, Yilmaz, Nafiye, Aktulay, Ayla, Bardakci, Yesim, Gulerman, Cavidan
• Format: Article
• Language: English
• Subjects: anti-Müllerian hormone; Antral follicle count; endometrioma; In vitro fertilization; ovarian response; Ovaries; Sperm
• ISSN: 0144-3615; 1364-6893
• DOI: 10.1080/01443615.2018.1533542

In this study, our aim was to determine which factor is more correlated with the number of oocytes retrieved in patients with endometrioma compared with controls undergoing in vitro fertilisation-intracytoplasmic sperm injection (IVF-ICSI) cycles: antral follicle count (AFC) or anti-Müllerian hormone (AMH). A total of 60 women with endometrioma and a control population of 60 women without endometrioma in the same period were randomly selected underwent the injection IVF-ICSI treatment. No significant differences were found between the groups in terms of age (28.78 ± 3.49 vs. 29.52 ± 2.47, p = .187), body mass index (23.62 ± 2.05 vs. 23.91 ± 2.11, p = .449), duration of infertility [(3 (2-4) vs. 3 (2-3), p = .139)], AMH level (1.52 ± 0.51 vs. 1.32 ± 0.92, p = .133), duration of stimulation [(9 (9-10) vs. 10 (9-10), p = .135)], total gonadotropin dose [(2750 (2262.5-3337.5) vs. 2770 (2680-3562.5), p = .125)], endometrial thickness [(10 (10-11) vs. 10 (9-11), p = .463)], fertilisation rates (67.20 ± 18.04 vs. 62.28 ± 17.13, p = .123), grade I embryo (43.3% vs. 30%, p = .185), clinical pregnancy rates (40% vs. 26.7%, p = .123), and the perinatal outcomes between the groups. The AFC was higher in the controls than in those with endometrioma (9.20 ± 1.80 vs. 6.32 ± 2.04, p